North Perth based biomedical company pSivida has announced that enrolment for a clinical trial of their Medidur product has begun.
The clinical trial will asses safety and effectiveness of the Medidur product, which is a small injectable intravitreal device, designed to release fluocinolone acetonide to the retina for up to three years.
Article continues...
This content you are trying to access is locked for subscribers only.